As the first batch of COVID-19 vaccine data is ready for analysis, Moderna stock price rises

Moderna Inc. MRNA,
+ 8.40%
The biotechnology company said that the first batch of data from its late-stage trial of the COVID-19 vaccine is ready for analysis, and the stock rose during the extended trading session on Wednesday. Monada shares rose 1% in after-hours trading after the stock rose 8.4% to close at $82.44. The company said that the first batch of data has been sent to the Data Security Monitoring Committee, involving 53 patients, some of whom received vaccinations and others received placebo treatment. In late October, Moderna completed the registration of the 30,000 participants in the study and said it was “actively preparing”

; to launch the vaccine. This year, Moderna stock rose 324%, while the S&P 500 index SPX rose 10.6%.
+ 0.76%.